Hostname: page-component-586b7cd67f-l7hp2 Total loading time: 0 Render date: 2024-11-23T05:53:28.990Z Has data issue: false hasContentIssue false
  • English
  • Français

Basic science: (JUNE 2008)

Published online by Cambridge University Press:  01 September 2008

R Sutherland
R Sutherland
Affiliation:
Cancer Research Program, Garvan Institute of Medical Research, Darlinghurst, NSW, Australia

Abstract

An abstract is not available for this content so a preview has been provided. As you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Image of the first page of this content. For PDF version, please use the ‘Save PDF’ preceeding this image.'
Type
Journals Watch
Information
Breast Cancer Online , Volume 11 , Issue 9 , September 2008 , e18
Copyright
Copyright © Cambridge University Press 2008

References

1.Akcakanat, A, Sahin, A, Shaye, AN, Velasco, MA, Meric-Bernstam, F. Comparison of Akt/mTOR signaling in primary breast tumors and matched distant metastases. Cancer 2008; 112: 2352–2358.Google Scholar
2.Apetoh, L, Tesniere, A, Ghiringhelli, F, Kroemer, G, Zitvogel, L. Molecular interactions between dying tumor cells and the innate immune system determine the efficacy of conventional anticancer therapies. Cancer Res 2008; 68: 4026–4030.CrossRefGoogle ScholarPubMed
3.Bartella, V, Cascio, S, Fiorio, E, Auriemma, A, Russo, A, Surmacz, E. Insulin-dependent leptin expression in breast cancer cells. Cancer Res 2008; 68: 4919–4927.CrossRefGoogle ScholarPubMed
4.Botlagunta, M, Vesuna, F, Mironchik, Y, Raman, A, Lisok, A, Winnard, P, Mukadam, S, Van Diest, P, Chen, JH, Farabaugh, P, Patel, AH, Raman, V. Oncogenic role of DDX3 in breast cancer biogenesis. Oncogene 2008; 27: 3912–3922.Google Scholar
5.Cappelletti, V, Gariboldi, M, De Cecco, L, Toffanin, S, Reid, JF, Lusa, L, Bajetta, E, Celio, L, Greco, M, Fabbri, A, Pierotti, MA, Daidone, MG. Patterns and changes in gene expression following neo-adjuvant anti-estrogen treatment in estrogen receptor-positive breast cancer. Endocr-Rel Cancer 2008; 15: 439–449.CrossRefGoogle ScholarPubMed
6.D’Assoro, AB, Busby, R, Acu, ID, Quatraro, C, Reinholz, MM, Farrugia, DJ, Schroeder, MA, Allen, C, Stivala, F, Galanis, E, Salisbury, JL. Impaired p53 function leads to centrosome amplification, acquired ER α phenotypic heterogeneity and distant metastases in breast cancer MCF-7 xenografts. Oncogene 2008; 27: 3901–3911.CrossRefGoogle ScholarPubMed
7.Dhar, G, Banerjee, S, Dhar, K, Tawfik, O, Mayo, MS, VanVeldhuizen, PJ, Banerjee, SK. Gain of oncogenic function of p53 mutants induces invasive phenotypes in human breast cancer cells by silencing CCN5/WISP-2. Cancer Res 2008; 68: 4580–4587.Google Scholar
8.Grady, D, Cauley, JA, Geiger, MJ, Kornitzer, M, Mosca, L, Collins, P, Wenger, NK, Song, J, Mershon, J, Barrett-Connor, E. Reduced incidence of invasive breast cancer with raloxifene among women at increased coronary risk. J Natl Cancer Inst 2008; 100: 854–861.Google Scholar
9.Hong, F, Larrea, MD, Doughty, C, Kwiatkowski, DJ, Squillace, R, Slingerland, JM. mTOR-raptor binds and activates SGK1 to regulate p27 phosphorylation. Mol Cell 2008; 30: 701–711.CrossRefGoogle ScholarPubMed
10.Kijima, I, Ye, J, Glackin, C, Chen, S. CCAAT/enhancer binding protein δ up-regulates aromatase promoters I.3/II in breast cancer epithelial cells. Cancer Res 2008; 68: 4455–4464.CrossRefGoogle ScholarPubMed
11.Kojima, Y, Akimoto, K, Nagashima, Y, Ishiguro, H, Shirai, S, Chishima, T, Ichikawa, Y, Ishikawa, T, Sasaki, T, Kubota, Y, Inayama, Y, Aoki, I, Ohno, S, Shimada, H. The overexpression and altered localization of the atypical protein kinase C λ/ι in breast cancer correlates with the pathologic type of these tumors. Hum Pathol 2008; 39: 824–831.Google Scholar
12.Lee, JY, Jang, KS, Shin, DH, Oh, MY, Kim, HJ, Kim, Y, Kong, G. Mel-18 negatively regulates INK4a/ARF-independent cell cycle progression via Akt inactivation in breast cancer. Cancer Res 2008; 68: 4201–4209.Google Scholar
13.Lipton, A, Leitzel, K, Chaudri-Ross, HA, Evans, DB, Ali, SM, Demers, L, Hamer, P, Brown-Shimer, S, Pierce, K, Gaur, V, Carney, W. Serum TIMP-1 and response to the aromatase inhibitor letrozole versus tamoxifen in metastatic breast cancer. J Clin Oncol 2008; 26: 2653–2658.CrossRefGoogle Scholar
14.Masri, S, Phung, S, Wang, X, Wu, XW, Yuan, YC, Wagman, L, Chen, S. Genome-wide analysis of aromatase inhibitor-resistant, tamoxifen-resistant, and long-term estrogen-deprived cells reveals a role for estrogen receptor. Cancer Res 2008; 68: 4910–4918.CrossRefGoogle ScholarPubMed
15.McAllister, SS, Gifford, AM, Greiner, AL, Kelleher, SP, Saelzler, MP, Ince, TA, Reinhardt, F, Harris, LN, Hylander, BL, Repasky, EA, Weinberg, RA. Systemic endocrine instigation of indolent tumor growth requires osteopontin. Cell 2008; 133: 994–1005.Google Scholar
16.Naderi, A, Hughes-Davies, L. A functionally significant cross-talk between androgen receptor and ErbB2 pathways in estrogen receptor negative breast cancer. Neoplasia 2008; 10: 542–548.CrossRefGoogle ScholarPubMed
17.Oxmann, D, Held-Feindt, J, Stark, AM, Hattermann, K, Yoneda, T, Mentlein, R. Endoglin expression in metastatic breast cancer cells enhances their invasive phenotype. Oncogene 2008; 27: 3567–3575.CrossRefGoogle ScholarPubMed
18.Park, CC, Zhang, HJ, Yao, ES, Park, CJ, Bissell, MJ. β(1) integrin inhibition dramatically enhances radiotherapy efficacy in human breast cancer xenografts. Cancer Res 2008; 68: 4398–4405.Google Scholar
19.Pervin, S, Tran, AH, Zekavati, S, Fulknto, JM, Singh, R, Chaudhuri, G. Increased susceptibility of breast cancer cells to stress mediated inhibition of protein synthesis. Cancer Res 2008; 68: 4862–4874.Google Scholar
20.Rabi, T, Banerjee, S. Novel synthetic triterpenoid methyl 25-hydroxy-3-oxoolean-12-en-28-oate induces apoptosis through JNK and p38 MAPK pathways in human breast adenocarcinoma MCF-7 cells. Mol Carcinog 2008; 47: 415–423.CrossRefGoogle ScholarPubMed
21.Rakha, EA, El-Sheikh, SE, Kandil, MA, El-Sayed, ME, Green, AR, Ellis, IO. Expression of BRCAI protein in breast cancer and its prognostic significance. Hum Pathol 2008; 39: 857–865.CrossRefGoogle Scholar
22.Salnis, GJ, Macedo, LF, Goloubeva, O, Schayowitz, A, Brodie, AMH. Stopping treatment can reverse acquired resistance to letrozole. Cancer Res 2008; 68: 4518–4524.Google Scholar
23.Shankar, E, Sivaprasad, U, Basu, A. Protein kinase C ε confers resistance of MCF-7 cells to TRAIL by Akt-dependent activation of Hdm2 and downregulation of p53. Oncogene 2008; 27: 3957–3966.CrossRefGoogle ScholarPubMed
24.Stacey, SN, Manolescu, A, Sulem, P, Thorlacius, S, Gudjonsson, SA, Jonsson, GF, Jakobsdottir, M, Bergthorsson, JT, Gudmundsson, J, Aben, KK, Strobbe, LJ, Swinkels, DW, van Engelenburg, KCA, Henderson, BE, Kolonel, LN, Le Marchand, L, Millastre, E, Andres, R, Saez, B, Lambea, J, Godino, J, Polo, E, Tres, A, Picelli, S, Rantala, J, Margolin, S, Jonsson, T, Sigurdsson, H, Jonsdottir, T, Hrafnkelsson, J, Johannsson, J, Sveinsson, T, Myrdal, G, Grimsson, HN, Sveinsdottir, SG, Alexiusdottir, K, Saemundsdottir, J, Sigurdsson, A, Kostic, J, Gudmundsson, L, Kristjansson, K, Masson, G, Fackenthal, JD, Adebamowo, C, Ogundiran, T, Olopade, OI, Haiman, CA, Lindblom, A, Mayordomo, JI, Kiemeney, LA, Gulcher, JR, Rafnar, T, Thorsteinsdottir, U, Johannsson, OT, Kong, A, Stefansson, K. Common variants on chromosome 5p12 confer susceptibility to estrogen receptor-positive breast cancer. Nat Genet 2008; 40: 703–706.CrossRefGoogle ScholarPubMed
25.Subtil-Rodriguez, A, Millan-Arino, L, Quiles, I, Ballare, C, Beato, M, Jordan, A. Progesterone induction of the 11 β-hydroxysteroid dehydrogenase type 2 promoter in breast cancer cells involves coordinated recruitment of STAT5A and progesterone receptor to a distal enhancer and polymerase tracking. Mol Cell Biol 2008; 28: 3830–3849.Google Scholar
26.Taddei, I, Deugnier, MA, Faraldo, MM, Petit, V, Bouvard, D, Medina, D, Fassler, R, Thiery, JP, Glukhova, MA. β 1 integrin deletion from the basal compartment of the mammary epithelium affects stem cells. Nat Cell Biol 2008; 10: 716–722.CrossRefGoogle Scholar
27.Urruticoechea, A, Aguilar, H, Sole, X, Capella, G, Martin, LA, Dowsett, M, Germa-Lluch, JR. Pre-clinical validation of early molecular markers of sensitivity to aromatase inhibitors in a mouse model of post-menopausal hormone-sensitive breast cancer. Breast Cancer Res Treatment 2008; 109: 463–470.CrossRefGoogle Scholar
28.Wallach-Dayan, SB, Rubinstein, AM, Hand, C, Breuer, R, Naor, D. DNA vaccination with CD44 variant isoform reduces mammary tumor local growth and lung metastasis. Mol Cancer Ther 2008; 7: 1615–1623.CrossRefGoogle ScholarPubMed
29.Zhang, M, Behbod, F, Atkinson, RL, Landis, MD, Kittrell, F, Edwards, D, Medina, D, Tsimelzon, A, Hilsenbeck, S, Green, JE, Michalowska, AM, Rosen, JM. Identification of tumor-initiating cells in a p53-null mouse model of breast cancer. Cancer Res 2008; 68: 4674–4682.CrossRefGoogle Scholar
30.Zhang, WH, Poh, A, Fanous, AA, Eastman, A. DNA damage-induced S phase arrest in human breast cancer depends on Chk1, but G(2) arrest can occur independently of Chk1, Chk2 or MAPKAPK2. Cell Cycle 2008; 7: 1668–1677.Google Scholar